BioMarin Pharma (BMRN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:02 PM EST- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year
- Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line
- Full-year 2016 Total BioMarin Revenue Guidance of Between $1.05 billion to $1.10 billion
- Company Anticipates Non-GAAP Breakeven or Better in 2017 Under all E.U. Outcomes with Kyndrisa
Financial Highlights ($ in millions, except per share data, unaudited)
  Three Months Ended December 31,  Twelve Months... More